Nir Eyal

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 23

Top Venues

Journal of medical ethics

mSphere

Bioethics

Clinical trials (London, England)

Rutgers The State University of New Jersey

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Rutgers The State University of New Jersey Jul 01 2019

United States

Henry Rutgers Professor of Bioethics, Director :: Center for Population-Level Bioethics

Publications

Nir Eyal, Melkizedeck Leshabari, Malabika Sarker
Dual-use research and research using enhanced pathogens in high-income countries: whose business? mSphere (2024)
Nir Eyal, Melkizedeck Leshabari, Malabika Sarker
Dual-use research and research using enhanced pathogens in high-income countries: whose business? mSphere 9 (7) (2024)
Adam Lerner, Nir Eyal
Future pandemics and the urge to 'do something'. Journal of medical ethics (2024)
Adam Lerner, Nir Eyal
Future pandemics and the urge to 'do something'. Journal of medical ethics (2024)
Nir Eyal, Melkizedeck Leshabari, Malabika Sarker
Dual-use research and research using enhanced pathogens in high-income countries: whose business? mSphere 9 (7) (2024)
Nir Eyal, Melkizedeck Leshabari, Malabika Sarker
Dual-use research and research using enhanced pathogens in high-income countries: whose business? mSphere 9 (7) (2024)
Nir Eyal, Bridget Williams
When offering a patient beneficial treatment undermines public health. Bioethics (2023)
Manne Sjöstrand, Nir Eyal
The phantasm of zero suicide. The British journal of psychiatry : the journal of mental science (2023)
Bastian Steuwer, Nir Eyal
Ethical and legal race-responsive vaccine allocation. Bioethics (2023)
Luchuo Engelbert Bain, Astrid Berner-Rodoreda, Shannon A McMahon, Malabika Sarker, Frank Tanser, Till Bärnighausen, Daniel Wikler, Nir Eyal
One lesson of COVID-19: Conduct more health policy trials. Proceedings of the National Academy of Sciences of the United States of America 119 (24) (2022)
Nir Eyal
Research ethics and public trust in vaccines: the case of COVID-19 challenge trials. Journal of medical ethics (2022)
Tobias Gerhard, Brian L Strom, Nir Eyal
Pandemic vaccine testing: Combining conventional and challenge studies. Pharmacoepidemiology and drug safety 31 (6) (2022)
Nir Eyal, Anca Gheaus, Axel Gosseries, Monica Magalhaes, Thierry Ngosso, Bastian Steuwer, Viroj Tangcharoensathien, Isa Trifan, Andrew Williams
Coronavirus Disease 2019 (COVID-19) Vaccine Prioritization in Low- and Middle-Income Countries May Justifiably Depart From High-Income Countries' Age Priorities. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 75 (Supplement_1) (2022)
Amirhossein Takian, Arefeh Mousavi, Martin Mckee, Vahid Yazdi-Feyzabad, Ronald Labonte, Viroj Tangcharoensathien, Ruairí Brugha, Elizabeth H Bradley, Lawrence O Gostin, Eivind Engebretsen, Nir Eyal, Sharon Friel, Victor G Rodwin, Ole Frithjof Norheim, Mohammad Hajizadeh, Naoki Ikegami, Agnes Binagwaho, Ilona Kickbusch, Aidin Aryankhesal, Ali Akbar Haghdoost
COP27: The Prospects and Challenges for the Middle East and North Africa (MENA). International journal of health policy and management 11 (12) (2022)
Kyungdo Lee, Nir Eyal
COVID-19 controlled human infection studies: worries about local community impact and demands for local engagement. Journal of medical ethics 47 (8) (2021)
Nir Eyal, Arthur L Caplan, Stanley Plotkin
COVID vaccine efficacy against the B.1.351 ("South African") variant-The urgent need to lay the groundwork for possible future challenge studies. Human vaccines & immunotherapeutics (2021)
Nir Eyal, Tobias Gerhard
Do coronavirus vaccine challenge trials have a distinctive generalisability problem? Journal of medical ethics (2021)
Nir Eyal
Study bystanders and ethical treatment of study participants-A proof of concept. Bioethics 34 (9) (2020)
Nir Eyal
Risk to bystanders in clinical trials: A symposium. Clinical trials (London, England) 16 (5) (2019)
Nir Eyal, Daniel Wikler
Ethical complexities of responding to bystander risk in HIV prevention trials. Clinical trials (London, England) 16 (5) (2019)
Nir Eyal, Jonathan Kimmelman, Lisa G Holtzman, Marc Lipsitch
Regulating impact on bystanders in clinical trials: An unsettled frontier. Clinical trials (London, England) 16 (5) (2019)
Marc Lipsitch, Nir Eyal
Improving vaccine trials in infectious disease emergencies. Science (New York, N.Y.) 357 (6347) (2018)
Rebecca Kahn, Annette Rid, Peter G Smith, Nir Eyal, Marc Lipsitch
Choices in vaccine trial design in epidemics of emerging infections. PLoS medicine 15 (8) (2018)

Nir Eyal.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nir Eyal